EGFR and neoplasm: Firstly, Ame55 has far less in vitro capacity than cetuximab in terms of tumor cell proliferation inhibition, apoptosis promotion, cell cycle arrest, migration inhibition, and anchoring growth inhibition (Supplemental Figure 3) and has lower suppression of EGFR and its downstream phosphorylation pathway.